Abstract
Gastroenteropancreatic neuroendocrine tumours (GEP NETs) represent a heterogenous family of tumours with growing incidence and challenging clinical management. Unlike other solid tumours, they have the ability to secrete different peptides and neuramines that cause distinct clinical syndromes. However, many are clinically silent until advanced disease. This guideline aims to provide practical recommendations for the diagnosis and treatment of GEP NETs. Most recent histological and staging classifications, as well as available therapeutic approaches, such as surgery, locoregional therapy, peptide receptor radionuclide therapy (PRRT) and hormonal or systemic therapy, are discussed in this manuscript, including some recent relevant achievements with novel targeted agents. Clinical presentation (with or without hormonal syndrome), histological tumour features (including proliferation index (Ki-67) and the presence or not of somatostatin receptors), tumour stage, and location of primary tumour and distant metastasis are all key issues that shall be taken into consideration to properly design and integrate the most adequate therapeutic strategy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794–1803
Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72
Kloppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27
Rindi G, Klöppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401
Rindi G, Klöppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762
Sobin L, Gospodarowicz M, Wittekind C (eds) (2010) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Oxford
García-Carbonero R (2007) Tratamiento pluridisciplinar de los tumores endocrinos gastroenteropancreáticos (TEGEP): propuesta de algoritmo terapéutico. In: Salazar R, Diaz JA, Halperin I, Sevilla I (eds) Manual GETNE. Diagnóstico y Tratamiento de los tumores neuroendocrinos de origen digestivo, 1st edn. TACTICS MD S.L., Grçaficas Rey S.L., pp 403–412
Rinke A, Müller HH, Schade-Brittinger C et al; PROMID Study Group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663
Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124–2130
Basu B, Sirohi B, Corrie P (2010) Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 17:R75–90
Niccoli P, Raoul J, Bang Y et al (2010) Updated safety and efficacy results of the phase III trial of sunitinib versus placebo for treatment of pancreatic neuroendocrine tumors. J Clin Oncol 28[15s]:(abstr 4000)
Yao JC, Shah MH, Ito T et al (2010) A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann Oncol 21[Suppl 8]: viii4 (LB A9)
Pavel M, Hainsworth JD, Baudin E et al (2010) A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus+octreotide LAR versus placebo+octreotide LAR in patients with advanced neuroendocrine tumors (RADIANT-2). Ann Oncol 21[Suppl 8]:viii4 (LB A8)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García-Carbonero, R., Salazar, R., Sevilla, I. et al. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol 13, 545–551 (2011). https://doi.org/10.1007/s12094-011-0695-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-011-0695-9